Nachrichten, Ressourcen, Aktuelles
Eine wissenschaftliche Plattform, die Sie über unsere neuesten Forschungsergebnisse und Unternehmensnachrichten auf dem Laufenden hält.
InnoSer completes a major milestone in the HEAL project with validated tumorigenicity assay
In a significant achievement, InnoSer has successfully validated tumorigenicity assay as part of the HEAL project, a major initiative aimed at accelerating the development of an allogeneic iPSC-based heart therapy. This milestone lays out the groundwork for safe and...
Einblick in die wichtigsten In-vitro-Dienstleistungen von InnoSer im Bereich der Onkologie: PD-1/PD-L1-Blockade-Assay
Immun-Checkpoint-Blockade in der onkologischen Wirkstoffforschung In den letzten Jahren hat sich die Immun-Checkpoint-Blockade als bahnbrechende therapeutische Strategie in der Immunonkologie etabliert. Der Programmierte-Zelltod-1-Rezeptor (PD-1) und sein Ligand, der Programmierte-Zelltod-Ligand 1 (PD-L1)...
InnoSer Announces Joint Initiative with Hasselt University/BIOMED to Support Preclinical Multiple Sclerosis Research
Researchers will benefit from InnoSer’s preclinical drug development expertise combined with Hasselt University’s foundational knowledge in Multiple Sclerosis (MS) to advance preclinical MS research. Diepenbeek, Belgium, October 16th, 2024 — InnoSer, a leading...
Invitation: Meet InnoSer at the upcoming Society for Neuroscience 2024 Chicago Meeting
We are thrilled to announce that InnoSer, as an innovative preclinical contract research organization (CRO) will be actively participating in the upcoming Society for Neuroscience 2024 Conference taking place in Chicago, US from Saturday 5th to 9th of October. ...
RENCA-Maus – Mausmodell für Nierenkrebs
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
Einführung in die CRO-Plattform von InnoSer für die präklinische Epilepsieforschung
Preclinical epilepsy-related research with InnoSer Broadly speaking, epilepsy is a large spectrum of distinct epileptic syndromes that differ in their etiologies, mechanisms, pathophysiological processes, associated comorbidities, and response profile to available...
info@innoserlaboratories.com